The UK and US have forged a landmark trade agreement that will maintain zero tariffs on British medicine products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase funding on pharmaceuticals through the public health system. This move ensures that duties on these vital exports will remain at zero for a period of 36 months.
This agreement comes after earlier threats to significantly raise duties on patented drug imports, with increases discussed reaching one hundred percent.
"This deal between the UK bolsters the global environment for cutting-edge drugs and establishes much-needed balance to American-British drug exports," a statement said.
Economic Importance
Drugs are one of the UK's most significant goods shipped to the America, which is by far the biggest buyer for large UK drugmakers.
Trade data indicate that in the one-year period leading up to the third quarter, the UK shipped medicines valued at £11.1bn to the US. This figure represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards work, stimulates capital expenditure and sets the stage for the UK to become a international leader for biotech and pharma," a government official remarked.
Specific British Pledges
The agreement includes several key changes from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to increase total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must return to the NHS to prevent overspending will be limited at 15%. Last year, repayments exceeded 20%.
Industry Background
This agreement comes amid a ongoing dispute between the sector and the UK government over medicine costs and NHS adoption.
These tensions were heightened by arguments that US consumers were charged a premium for the equivalent treatments than people in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or abandoned, while major expansions have been announced toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the last ten years.
